{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:22:10Z","timestamp":1791404530854,"version":"4.3.3"},"reference-count":235,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wroclaw Medical University","award":["SUBZ.A430.24.049"],"award-info":[{"award-number":["SUBZ.A430.24.049"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>This literature review provides a comprehensive overview of triple-negative breast cancer (TNBC) and explores innovative targeted therapies focused on specific hallmarks of cancer cells, aiming to revolutionize breast cancer treatment. TNBC, characterized by its lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), presents distinct features, categorizing these invasive breast tumors into various phenotypes delineated by key elements in molecular assays. This article delves into the latest advancements in therapeutic strategies targeting components of the tumor microenvironment and pivotal hallmarks of cancer: deregulating cellular metabolism and the Warburg effect, acidosis and hypoxia, the ability to metastasize and evade the immune system, aiming to enhance treatment efficacy while mitigating systemic toxicity. Insights from in vitro and in vivo studies and clinical trials underscore the promising effectiveness and elucidate the mechanisms of action of these novel therapeutic interventions for TNBC, particularly in cases refractory to conventional treatments. The integration of targeted therapies tailored to the molecular characteristics of TNBC holds significant potential for optimizing clinical outcomes and addressing the pressing need for more effective treatment options for this aggressive subtype of breast cancer.<\/jats:p>","DOI":"10.3390\/cancers16081483","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T03:56:13Z","timestamp":1713153373000},"page":"1483","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment\u2014In Vitro, In Vivo and Clinical Trials Literature Review"],"prefix":"10.3390","volume":"16","author":[{"given":"Anna","family":"Szulc","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Pathology, Division of General and Experimental Pathology, Wroclaw Medical University, 50-368 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-6330","authenticated-orcid":false,"given":"Marta","family":"Wo\u017aniak","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Pathology, Division of General and Experimental Pathology, Wroclaw Medical University, 50-368 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.yexcr.2010.02.045","article-title":"Hallmarks of Cancer: Interactions with the Tumor Stroma","volume":"316","author":"Pietras","year":"2010","journal-title":"Exp. Cell Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Karim, A.M., Eun Kwon, J., Ali, T., Jang, J., Ullah, I., Lee, Y.G., Park, D.W., Park, J., Jeang, J.W., and Kang, S.C. (2023). Triple-negative Breast Cancer: Epidemiology, Molecular Mechanisms, and Modern Vaccine-based Treatment Strategies. Biochem. Pharmacol., 212.","DOI":"10.1016\/j.bcp.2023.115545"},{"key":"ref_5","unstructured":"OECD (2023). Krajowe Profile Dotycz\u0105ce Nowotwor\u00f3w: Polska 2023, OECD."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"20211033","DOI":"10.1259\/bjr.20211033","article-title":"Understanding Breast Cancer as a Global Health Concern","volume":"95","author":"Wilkinson","year":"2022","journal-title":"Br. J. Radiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molonc.2010.04.004","article-title":"Histological Types of Breast Cancer: How Special Are They?","volume":"4","author":"Weigelt","year":"2010","journal-title":"Mol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.12688\/f1000research.18888.1","article-title":"Triple-negative Breast Cancer: Recent Treatment Advances","volume":"8","author":"Bergin","year":"2019","journal-title":"F1000Research"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","article-title":"An Overview of Triple-Negative Breast Cancer","volume":"293","author":"Kumar","year":"2015","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.7314\/APJCP.2014.15.6.2427","article-title":"Triple Negative Breast Cancer","volume":"15","author":"Cetin","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nedeljkovi\u0107, M., and Damjanovi\u0107, A. (2019). Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells, 8.","DOI":"10.3390\/cells8090957"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","article-title":"Triple-negative Breast Cancer: Promising Prognostic Biomarkers Currently in Development","volume":"21","author":"Sukumar","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.semcancer.2020.06.005","article-title":"Pathology of Triple Negative Breast Cancer","volume":"72","author":"Borri","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Medina, M.A., Oza, G., Sharma, A., Arriaga, L.G., Hern\u00e1ndez Hern\u00e1ndez, J.M., Rotello, V.M., and Ramirez, J.T. (2020). Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17062078"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.17925\/EOH.2014.10.1.43","article-title":"Oncoplasty as the Standard of Care in Breast Cancer Surgery","volume":"1","author":"Urban","year":"2014","journal-title":"Eur. Oncol. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.breast.2014.06.012","article-title":"Sexual Functioning in Women After Mastectomy Versus Breast Conserving Therapy for Early-Stage Breast Cancer: A Prospective Controlled Study","volume":"23","author":"Aerts","year":"2014","journal-title":"Breast"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.25122\/jml-2021-0108","article-title":"Triple-negative Breast Cancer: Current Treatment Strategies and Factors of Negative Prognosis","volume":"15","author":"Baranova","year":"2022","journal-title":"J. Med. Life"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1080\/14656566.2020.1746273","article-title":"Neoadjuvant or Adjuvant Chemotherapy in Early Breast Cancer?","volume":"21","author":"Montemurro","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","article-title":"Pembrolizumab and Atezolizumab in Triple-negative Breast Cancer","volume":"70","author":"Kwapisz","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple-negative Breast Cancer Therapy: Current and Future Perspectives","volume":"57","author":"Won","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"a041332","DOI":"10.1101\/cshperspect.a041332","article-title":"Immunotherapy Approaches for Breast Cancer Patients in 2023","volume":"13","author":"Emens","year":"2023","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1101\/gad.334516.119","article-title":"PARP And PARG Inhibitors in Cancer Treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15330338221145246","DOI":"10.1177\/15330338221145246","article-title":"Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review","volume":"22","author":"Lu","year":"2023","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the Origin of Cancer Cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.pharmthera.2012.11.003","article-title":"The Warburg effect: Insights from the past decade","volume":"137","author":"Upadhyay","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1113\/JP278810","article-title":"Revisiting the Warburg effect: Historical dogma versus current understanding","volume":"599","author":"Vaupel","year":"2021","journal-title":"J. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/09553002.2019.1589653","article-title":"The Warburg effect: Essential part of metabolic reprogramming and central contributor to cancer progression","volume":"95","author":"Vaupel","year":"2019","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: The metabolic requirements of cell proliferation","volume":"324","author":"Cantley","year":"2009","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Boese, A.C., and Kang, S. (2021). Mitochondrial metabolism-mediated redox regulation in cancer progression. Redox Biol., 42.","DOI":"10.1016\/j.redox.2021.101870"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1039\/C9ME00175A","article-title":"Potentiating Anti-Cancer Chemotherapeutics and Antimicrobials via Sugar-Mediated Strategies","volume":"5","author":"Mullapudi","year":"2020","journal-title":"Mol. Syst. Des. Eng."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0190-9622(97)70174-9","article-title":"Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia","volume":"37","author":"Baer","year":"1997","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/jcp.20166","article-title":"Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer","volume":"202","author":"Macheda","year":"2005","journal-title":"J. Cell. Physiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000104457","article-title":"Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: Novel pathways and targets for anticancer therapeutics","volume":"53","author":"Airley","year":"2007","journal-title":"Chemotherapy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1590\/S1807-59322011000600008","article-title":"GLUT1 Expression in Malignant Tumors and Its Use as an Immunodiagnostic Marker","volume":"66","author":"Carvalho","year":"2011","journal-title":"Clinics"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.metabol.2015.10.007","article-title":"Facilitative Glucose Transporters: Implications for Cancer Detection, Prognosis and Treatment","volume":"65","author":"Barron","year":"2016","journal-title":"Metabolism"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2967\/jnumed.108.054205","article-title":"18F-FDG PET and PET\/CT in the Evaluation of Cancer Treatment Response","volume":"50","author":"Ell","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Pastuch-Gawo\u0142ek, G., Szreder, J., Domi\u0144ska, M., Pielok, M., Cichy, P., and Grymel, M. (2023). A Small Sugar Molecule with Huge Potential in Targeted Cancer Therapy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030913"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/1878-0261.12530","article-title":"SGLT1 is required for the survival of triple-negative breast cancer cells via potentiation of EGFR activity","volume":"13","author":"Liu","year":"2019","journal-title":"Mol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s00404-011-2166-5","article-title":"Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma","volume":"285","author":"Lai","year":"2012","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s10266-011-0033-2","article-title":"Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma","volume":"100","author":"Hanabata","year":"2012","journal-title":"Odontology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1080\/07357900801956363","article-title":"Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival","volume":"26","author":"Casneuf","year":"2008","journal-title":"Cancer Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.cmet.2018.05.014","article-title":"Obesity protects cancer from drugs targeting blood vessels","volume":"27","author":"Cao","year":"2018","journal-title":"Cell Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e131596","DOI":"10.1172\/jci.insight.131596","article-title":"GLUT5-mediated fructose utilization drives lung cancer growth by stimulating fatty acid synthesis and AMPK\/mTORC1 signaling","volume":"5","author":"Chen","year":"2020","journal-title":"JCI Insight"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1432-1033.1997.00001.x","article-title":"The mitochondrial carnitine palmitoyltransferase system from concept to molecular analysis","volume":"244","author":"McGarry","year":"1997","journal-title":"Eur. J. Biochem."},{"key":"ref_47","first-page":"687","article-title":"Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer","volume":"32","author":"Vellon","year":"2017","journal-title":"Histol. Histopathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.trsl.2017.07.004","article-title":"Deciphering metabolic rewiring in breast cancer subtypes","volume":"189","author":"Ogrodzinski","year":"2017","journal-title":"Transl. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nm.4055","article-title":"Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer","volume":"22","author":"Camarda","year":"2016","journal-title":"Nat. Med."},{"key":"ref_50","first-page":"213","article-title":"Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts","volume":"60","author":"Pizer","year":"2000","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/A:1020833410523","article-title":"(-)-Epigallocatechin (EGC) of green tea induces apoptosis of human breast cancer cells but not of their normal counterparts","volume":"76","author":"Vergote","year":"2002","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/sj.tpj.6500192","article-title":"Suppression of fatty acid synthase in MCF-7 breast cancer cells by tea and tea polyphenols: A possible mechanism for their hypolipidemic effects","volume":"3","author":"Yeh","year":"2003","journal-title":"Pharmacogenom. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1158\/1078-0432.CCR-04-1976","article-title":"Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems","volume":"11","author":"Baliga","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10549-007-9678-5","article-title":"Fatty acid metabolism in breast cancer cells: Differential inhibitory effects of epigallocatechin gallate (EGCG) and C75","volume":"109","author":"Puig","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Mar\u00edn, V., Burgos, V., P\u00e9rez, R., Maria, D.A., Pardi, P., and Paz, C. (2023). The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310737"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13058-018-0946-6","article-title":"The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumors","volume":"20","author":"Craze","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1038\/onc.2015.381","article-title":"ASCT2\/SLC1A5 controls glutamine uptake and tumor growth in triple-negative basal-like breast cancer","volume":"35","author":"Wang","year":"2016","journal-title":"Oncogene"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Cao, M.D., Lamichhane, S., Lundgren, S., Bofin, A., Fjosne, H., Giskeodegard, G.F., and Bathen, T.F. (2014). Metabolic characterization of triple negative breast cancer. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-941"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1073\/pnas.1112495109","article-title":"Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism","volume":"109","author":"Cassago","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bbcan.2018.07.007","article-title":"Glutaminase isoenzymes in the metabolic therapy of cancer","volume":"1870","year":"2018","journal-title":"Biochim. Biophys. Acta\u2014Rev. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.bmc.2016.03.009","article-title":"Design and evaluation of novel glutaminase inhibitors","volume":"24","author":"McDermott","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40169-018-0185-6","article-title":"Analyses of Repeated Failures in Cancer Therapy for Solid Tumors: Poor Tumor-selective Drug Delivery, Low Therapeutic Efficacy and Unsustainable Costs","volume":"7","author":"Maeda","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A View on Drug Resistance in Cancer","volume":"575","author":"Hyman","year":"2019","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1039\/D0NJ04134C","article-title":"Small Molecule Drug Conjugates (SMDCs): An Emerging Strategy for Anticancer Drug Design and Discovery","volume":"45","author":"Patel","year":"2021","journal-title":"New J. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5306\/wjco.v11.i3.110","article-title":"Glycoconjugation: An Approach to Cancer Therapeutics","volume":"11","author":"Molejon","year":"2020","journal-title":"World J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"108195","DOI":"10.1016\/j.carres.2020.108195","article-title":"Glycoconjugates for glucose transporter-mediated cancer-specific targeting and treatment","volume":"498","author":"Fu","year":"2020","journal-title":"Carbohydr. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1517\/13543784.2012.670218","article-title":"Glufosfamide: Can we improve the process of anticancer agent development?","volume":"21","author":"Lacombe","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1054\/bjoc.1999.0974","article-title":"Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumor therapeutic agent","volume":"82","author":"Seker","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/jphp.12539","article-title":"Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism","volume":"68","author":"Meredith","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"ref_71","first-page":"1","article-title":"Anthracyclines in the treatment of cancer. An overview","volume":"54","author":"Hortobagyi","year":"1997","journal-title":"Drugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: An evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bjc.6605587","article-title":"Influence of Pharmacogenetics on Response and Toxicity in Breast Cancer Patients Treated with Doxorubicin and Cyclophosphamide","volume":"102","author":"Bray","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Gomes, B.C., Honrado, M., Armada, A., Viveiros, M., Rueff, J., and Rodrigues, A.S. (2020). ABC Efflux Transporters and the Circuitry of MiRNAs: Kinetics of Expression in Cancer Drug Resistance. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082985"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3892\/ol.2015.3508","article-title":"Interplay between unfolded protein response and autophagy promotes tumor drug resistance","volume":"10","author":"Yan","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.tcb.2013.07.006","article-title":"Evading apoptosis in cancer","volume":"23","author":"Fernald","year":"2013","journal-title":"Trends Cell Biol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bmcl.2009.12.084","article-title":"Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents","volume":"20","author":"Hu","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.bcp.2011.04.010","article-title":"DNA interactions of 2-pyrrolinodoxorubicin, a distinctively more potent daunosamine-modified analogue of doxorubicin","volume":"82","author":"Stepankova","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-06-3717","article-title":"2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells","volume":"67","author":"Simons","year":"2007","journal-title":"Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0360-3016(96)85017-6","article-title":"Improving cancer radiotherapy with 2-deoxy-D-glucose: Phase I\/II clinical trials on human cerebral gliomas","volume":"35","author":"Mohanti","year":"1996","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/0008-5472.CAN-03-3294","article-title":"2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo","volume":"64","author":"Maschek","year":"2004","journal-title":"Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.2174\/0929867054637626","article-title":"Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches","volume":"12","author":"Galanski","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.1002\/chem.201000148","article-title":"Advances in platinum chemotherapeutics","volume":"16","author":"Harper","year":"2010","journal-title":"Chem.\u2014Eur. J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"8113","DOI":"10.1039\/c0dt00292e","article-title":"The status of platinum anticancer drugs in the clinic and in clinical trials","volume":"39","author":"Wheate","year":"2010","journal-title":"Dalton Trans."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"7","DOI":"10.13005\/bpj\/1608","article-title":"Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin","volume":"12","author":"Aldossary","year":"2019","journal-title":"Biomed. Pharmacol. J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ctrv.2004.12.006","article-title":"Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy","volume":"31","author":"Kweekel","year":"2005","journal-title":"Cancer Treat. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"31456","DOI":"10.1021\/acsomega.0c05168","article-title":"Experimental and Computational Investigations of Carboplatin Supramolecular Complexes","volume":"5","author":"Fahmy","year":"2020","journal-title":"ACS Omega"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Fahmy, S.A., Br\u00fc\u00dfler, J., Alawak, M., El-Sayed, M.M., Bakowsky, U., and Shoeib, T. (2019). Chemotherapy Based on Supramolecular Chemistry: A Promising Strategy in Cancer Therapy. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11060292"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/TCRM.S3583","article-title":"Role of oxaliplatin in the treatment of colorectal cancer","volume":"5","author":"Comella","year":"2009","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nano.2009.03.002","article-title":"Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer","volume":"6","author":"Jain","year":"2010","journal-title":"Nanomedicine"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/ndt\/gfh826","article-title":"Renal toxicity of oxaliplatin","volume":"20","author":"Labaye","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-3-12","article-title":"Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: Two case reports and a review of the literature","volume":"3","author":"Bautista","year":"2010","journal-title":"J. Hematol. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1517\/17425247.2012.642362","article-title":"Methotrexate: A detailed review on drug delivery and clinical aspects","volume":"9","author":"Khan","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and Managing Toxicities of High-Dose Methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"ref_95","first-page":"287","article-title":"Toxicity of low dose methotrexate in rheumatoid arthritis","volume":"16","year":"2007","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_96","first-page":"1017","article-title":"Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: A systematic review of the literature","volume":"27","author":"Visser","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00280-012-2062-0","article-title":"A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis","volume":"71","author":"Abolmaali","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_98","first-page":"341","article-title":"Accumulation of methotrexate in human tissues following high-dose methotrexate therapy","volume":"48","author":"Iqbal","year":"1998","journal-title":"J. Pak. Med. Assoc."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1606628","DOI":"10.1002\/adma.201606628","article-title":"Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization","volume":"29","author":"Sun","year":"2017","journal-title":"Adv. Mater."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Luo, Z., Wu, Y., Li, Z., and Loh, X.J. (2019). Recent Progress in Polyhydroxyalkanoates-Based Copolymers for Biomedical Applications. Biotechnol. J., 14.","DOI":"10.1002\/biot.201900283"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.progpolymsci.2017.05.002","article-title":"Advances in drug delivery systems based on synthetic poly(hydroxybutyrate) (co)polymers","volume":"73","author":"Barouti","year":"2017","journal-title":"Prog. Polym. Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1475-2867-13-89","article-title":"Acidic extracellular microenvironment and cancer","volume":"13","author":"Kato","year":"2013","journal-title":"Cancer Cell Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e1800917","DOI":"10.1002\/marc.201800917","article-title":"pH-Responsive Polymer Nanoparticles for Drug Delivery","volume":"40","author":"Deirram","year":"2019","journal-title":"Macromol. Rapid Commun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.biomaterials.2016.01.061","article-title":"Mechanisms and biomaterials in pH-responsive tumor targeted drug delivery: A review","volume":"85","author":"Kanamala","year":"2016","journal-title":"Biomaterials"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/mp100253e","article-title":"pH-Responsive Nanoparticles for Drug Delivery","volume":"7","author":"Gao","year":"2010","journal-title":"Mol. Pharm."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejps.2016.12.011","article-title":"Hydrazone linkages in pH responsive drug delivery systems","volume":"99","author":"Sonawane","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijpharm.2017.11.003","article-title":"Mechanisms of drug release in pH-sensitive micelles for tumor targeted drug delivery system: A review","volume":"535","author":"Wang","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1073\/pnas.0700223104","article-title":"Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation","volume":"104","author":"Abraham","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2174\/1381612023394485","article-title":"Beta-glucuronidase-mediated drug release","volume":"8","author":"Boven","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2006.02.027","article-title":"A folate receptor-targeted liposomal formulation for paclitaxel","volume":"316","author":"Wu","year":"2006","journal-title":"Int. J. Pharm."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/17425255.2021.1943358","article-title":"Current opinion on the pharmacogenomics of paclitaxel-induced toxicity","volume":"17","author":"AlAhmad","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1517\/14740338.6.5.609","article-title":"Paclitaxel: A review of adverse toxicities and novel delivery strategies","volume":"6","author":"Marupudi","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Shan, X., Fu, Y.S., Aziz, F., Wang, X.Q., Yan, Q., and Liu, J.W. (2014). Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115401"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1248\/bpb.17.635","article-title":"Inhibition of tumor angiogenesis and metastasis by a saponin of Panax ginseng, ginsenoside-Rb2","volume":"17","author":"Sato","year":"1994","journal-title":"Biol. Pharm. Bull."},{"key":"ref_116","first-page":"4376","article-title":"Treatment with 20(S)-ginsenoside Rg3 reverses multidrug resistance in A549\/DDP xenograft tumors","volume":"15","author":"Liu","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/cas.13881","article-title":"20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma","volume":"110","author":"Chen","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.7150\/thno.34953","article-title":"Novel ginsenoside-based multifunctional liposomal delivery system for combination therapy of gastric cancer","volume":"9","author":"Hong","year":"2019","journal-title":"Theranostics"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jconrel.2020.12.036","article-title":"Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy","volume":"330","author":"Zhu","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1101\/gad.1243304","article-title":"The biology of hypoxia: The role of oxygen sensing in development, normal function, and disease","volume":"18","author":"Giaccia","year":"2004","journal-title":"Genes Dev."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cell.2009.01.020","article-title":"Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization","volume":"136","author":"Mazzone","year":"2009","journal-title":"Cell"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00441-016-2461-3","article-title":"Hypoxia in tissue repair and fibrosis","volume":"365","author":"Darby","year":"2016","journal-title":"Cell Tissue Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1055\/s-0030-1253454","article-title":"Heterogeneity of the tumor vasculature","volume":"36","author":"Nagy","year":"2010","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.critrevonc.2004.07.002","article-title":"Mutational spectrum of p53 mutations in primary breast and ovarian tumors","volume":"52","author":"Feki","year":"2004","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semcancer.2008.11.009","article-title":"Regulation of cancer cell metabolism by hypoxia-inducible factor 1","volume":"19","author":"Semenza","year":"2009","journal-title":"Semin. Cancer Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.bjc.6603922","article-title":"Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer","volume":"97","author":"Gatenby","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1074\/jbc.M511397200","article-title":"The plasma membrane lactate transporter MCT4, but not MCT1 is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism","volume":"281","author":"Ullah","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ccr.2008.05.005","article-title":"Tumor cell metabolism: Cancer\u2019s Achilles\u2019 heel","volume":"6","author":"Kroemer","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/path.1120","article-title":"Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2","volume":"197","author":"Bartosova","year":"2002","journal-title":"J. Pathol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: Role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1074\/jbc.M111.286062","article-title":"Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain","volume":"287","author":"Svastova","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/onc.2015.273","article-title":"Disrupting Na+, HCO3\u2212-cotransporter NBCn1 (Slc4a7) delays murine breast cancer development","volume":"35","author":"Lee","year":"2016","journal-title":"Oncogene"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-11-1877","article-title":"Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy","volume":"18","author":"McIntyre","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/jcp.24930","article-title":"The Na(+)\/HCO3(-) Co-Transporter SLC4A4 Plays a Role in Growth and Migration of Colon and Breast Cancer Cells","volume":"230","author":"Parks","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"130","DOI":"10.18632\/oncotarget.2766","article-title":"Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells","volume":"6","author":"Shiraishi","year":"2015","journal-title":"Oncotarget"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1126\/science.aaf4405","article-title":"Hypoxic control of metastasis","volume":"352","author":"Rankin","year":"2016","journal-title":"Science"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2217\/fon.09.94","article-title":"Epithelial to mesenchymal transition in development of cancer","volume":"8","author":"Micalizzi","year":"2009","journal-title":"Future Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1007\/s13277-015-4361-7","article-title":"Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers","volume":"37","author":"Scimeca","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumors. Nature, 490, 61\u201370.","DOI":"10.1038\/nature11412"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Liu, Q., Guan, C., Liu, C., Li, H., Wu, J., and Sun, C. (2022). Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy. Biomed. Pharmacother., 156.","DOI":"10.1016\/j.biopha.2022.113861"},{"key":"ref_141","first-page":"730","article-title":"Histotripsy focused ultrasound ablation induces immunological cell death in treated and distant untreated tumors","volume":"8","author":"Pepple","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/MD.0000000000004766","article-title":"Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance","volume":"95","author":"Chang","year":"2016","journal-title":"Medicine"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.stem.2012.05.007","article-title":"Cancer stem cells: Current status and evolving complexities","volume":"10","author":"Visvader","year":"2012","journal-title":"Cell Stem Cell"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.7150\/jca.19079","article-title":"Epithelial-mesenchymal transition: A potential regulator of ABC transporters in tumor progression","volume":"8","author":"Jiang","year":"2017","journal-title":"J. Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0945-053X(98)90012-9","article-title":"Lysyl oxidase: Properties, regulation and multiple functions in biology","volume":"16","author":"Kagan","year":"1998","journal-title":"Matrix Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/jcb.21371","article-title":"Paradoxical roles for lysyl oxidases in cancer\u2014A prospect","volume":"101","author":"Payne","year":"2007","journal-title":"J. Cell. Biochem."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2217\/fon.12.105","article-title":"LOXL2 in epithelial cell plasticity and tumor progression","volume":"8","author":"Cano","year":"2012","journal-title":"Future Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/0008-5472.CAN-10-2868","article-title":"LOXL2-mediated matrix remodeling in metastasis and mammary gland involution","volume":"71","author":"Barker","year":"2011","journal-title":"Cancer Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"32893","DOI":"10.18632\/oncotarget.9073","article-title":"Potential options for managing LOX+ER-breast cancer patients","volume":"7","author":"Han","year":"2016","journal-title":"Oncotarget"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anndiagpath.2018.03.009","article-title":"Overexpression of Lox in triple-negative breast cancer","volume":"34","author":"Leo","year":"2018","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4048\/jbc.2016.19.3.223","article-title":"Molecular Classification of Triple-Negative Breast Cancer","volume":"19","author":"Ahn","year":"2016","journal-title":"J. Breast Cancer"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10549-013-2662-3","article-title":"LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients","volume":"141","author":"Ahn","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/jcb.21517","article-title":"Hypoxia\/reoxygenation: A dynamic regulator of lysyl oxidase-facilitated breast cancer migration","volume":"103","author":"Postovit","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1182\/blood-2010-10-313296","article-title":"Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane","volume":"118","author":"Bignon","year":"2011","journal-title":"Blood"},{"key":"ref_155","first-page":"10260","article-title":"Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition","volume":"234","author":"Kools","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.neo.2019.03.003","article-title":"Lysyl Oxidase-Like Protein 2 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer","volume":"21","author":"Wang","year":"2019","journal-title":"Neoplasia"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1021\/ja01615a052","article-title":"Isolation, Structure and Synthesis of a Lathyrus Factor From L. Odoratus","volume":"77","author":"Schilling","year":"1955","journal-title":"J. Am. Chem. Soc."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1510\/icvts.2010.239681","article-title":"In search of a new therapeutic target for the treatment of genetically triggered thoracic aortic aneurysms and cardiovascular conditions: Insights from human and animal lathyrism","volume":"11","author":"Sherif","year":"2010","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Bondareva, A., Downey, C.M., Ayres, F., Liu, W., Boyd, S.K., Hallgrimsson, B., and Jirik, F.R. (2009). The Lysyl Oxidase Inhibitor, \u03b2-Aminopropionitrile, Diminishes the Metastatic Colonization Potential of Circulating Breast Cancer Cells. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005620"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1021\/acs.jmedchem.9b01112","article-title":"2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth","volume":"63","author":"Smithen","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm.2208","article-title":"Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment","volume":"16","author":"Spangler","year":"2010","journal-title":"Nat. Med."},{"key":"ref_162","first-page":"2366","article-title":"Lysyl Oxidase Like-2 (LOXL2): An Emerging Oncology Target","volume":"3","author":"Chopra","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1096\/fj.201801860RR","article-title":"Lysyl oxidase-like 2 (LOXL2)-mediated cross-linking of tropoelastin","volume":"33","author":"Schmelzer","year":"2019","journal-title":"FASEB J."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ijc.24308","article-title":"Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells","volume":"125","author":"Hollosi","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_165","unstructured":"(2023, December 10). Pharmaxis. Available online: https:\/\/www.pharmaxis.com.au\/investor-centre\/news\/view\/pharmaxis-releases-positive-results-of-phase-1-clinical-trial-for-second-loxl2-inhibitor-compound."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer Immunoediting: Integrating Immunity\u2019s Roles in Cancer Suppression and Promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1172\/JCI45816","article-title":"Human breast cancer cells enhance self-tolerance by promoting evasion from NK cell antitumor immunity","volume":"121","author":"Mamessier","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10549-016-3863-3","article-title":"Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00","volume":"158","author":"Pruneri","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0304-3835(92)90174-T","article-title":"Flow cytometric analysis of tumor infiltrating lymphocyte activation and tumor cell MHC class I and II expression in breast cancer patients","volume":"61","author":"Whitford","year":"1992","journal-title":"Cancer Lett."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Marra, A., Viale, G., and Curigliano, G. (2019). Recent advances in triple negative breast cancer: The immunotherapy era. BMC Med., 17.","DOI":"10.1186\/s12916-019-1326-5"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","article-title":"Exploiting the mutanome for tumor vaccination","volume":"72","author":"Castle","year":"2012","journal-title":"Cancer Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1101\/gr.165985.113","article-title":"Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival","volume":"24","author":"Brown","year":"2014","journal-title":"Genome Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2014-04-567933","article-title":"Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia","volume":"124","author":"Rajasagi","year":"2014","journal-title":"Blood"},{"key":"ref_176","first-page":"1","article-title":"CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion","volume":"40","author":"Dadmarz","year":"1995","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","article-title":"Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: The long and winding road to solid tumors","volume":"9","author":"Zizzari","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: Chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol. Rev."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Kim, D.W., and Cho, J.Y. (2020). Recent Advances in Allogeneic CAR-T Cells. Biomolecules, 10.","DOI":"10.3390\/biom10020263"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: Next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7150\/jca.48976","article-title":"Current Progress in CAR-T Cell Therapy for Hematological Malignancies","volume":"12","author":"Han","year":"2021","journal-title":"J. Cancer"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41434-021-00246-w","article-title":"Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany","volume":"28","author":"Albinger","year":"2021","journal-title":"Gene Ther."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Martinez, M., and Moon, E.K. (2019). CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00128"},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Knochelmann, H.M., Smith, A.S., Dwyer, C.J., Wyatt, M.M., Mehrotra, S., and Paulos, C.M. (2018). CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01740"},{"key":"ref_195","unstructured":"(2024, March 22). UPMC Hillman Cancer Center. Available online: https:\/\/hillman.upmc.com\/mario-lemieux-center\/treatment\/car-t-cell-therapy\/fda-approved-therapies."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Abbott, R.C., Cross, R.S., and Jenkins, M.R. (2020). Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020515"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","article-title":"The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer","volume":"35","author":"Hsu","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1034\/j.1600-065X.2002.18803.x","article-title":"Cancer\/testis antigens: An expanding family of targets for cancer immunotherapy","volume":"188","author":"Scanlan","year":"2002","journal-title":"Immunol. Rev."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1158\/1535-7163.MCT-20-0385","article-title":"Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer","volume":"19","author":"Dees","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.7150\/ijbs.70120","article-title":"CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application","volume":"18","author":"Yang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1158\/1535-7163.MCT-14-0132","article-title":"Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers","volume":"13","author":"Alewine","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11427-016-5027-4","article-title":"Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors","volume":"59","author":"Zhang","year":"2016","journal-title":"Sci. China Life Sci."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","article-title":"Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment","volume":"69","author":"Harlin","year":"2009","journal-title":"Cancer Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current Progress in CAR-T Cell Therapy for Solid Tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat. Med."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T Cell Therapy for Solid Tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood.V99.9.3179","article-title":"Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity","volume":"99","author":"Bollard","year":"2002","journal-title":"Blood"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"e988098","DOI":"10.4161\/21505594.2014.988098","article-title":"Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors","volume":"4","author":"Nishio","year":"2015","journal-title":"Oncoimmunology."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"e26286","DOI":"10.4161\/onci.26286","article-title":"Blockade of PD-1 immunosuppression boosts CAR T-cell therapy","volume":"2","author":"John","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/mt.2013.110","article-title":"Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma","volume":"21","author":"Kakarla","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"e1284722","DOI":"10.1080\/2162402X.2017.1284722","article-title":"PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells","volume":"6","author":"Wei","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"104112","DOI":"10.1016\/j.cellimm.2020.104112","article-title":"Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in a mouse model","volume":"352","author":"Song","year":"2020","journal-title":"Cell. Immunol."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"De Toro, J., Herschlik, L., Waldner, C., and Mongini, C. (2015). Emerging roles of exosomes in normal and pathological conditions: New insights for diagnosis and therapeutic applications. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00203"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1172\/JCI81137","article-title":"Dendritic cell-derived exosomes for cancer therapy","volume":"126","author":"Pitt","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12026-018-9000-0","article-title":"Role of T cell-derived exosomes in immunoregulation","volume":"66","author":"Lu","year":"2018","journal-title":"Immunol. Res."},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Wu, S.W., Li, L., Wang, Y., and Xiao, Z. (2019). CTL-Derived Exosomes Enhance the Activation of CTLs Stimulated by Low-Affinity Peptides. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01274"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1038\/s41467-019-12321-3","article-title":"CAR exosomes derived from effector CAR-T cells have potent antitumor effects and low toxicity","volume":"10","author":"Fu","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1158\/0008-5472.CAN-12-2072","article-title":"Targeted Cancer Therapy with a 2-Deoxyglucose--Based Adriamycin Complex","volume":"73","author":"Cao","year":"2013","journal-title":"Cancer Res."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1039\/c3cc38589b","article-title":"Highly water-soluble platinum(II) complexes as GLUT substrates for targeted therapy: Improved anticancer efficacy and transporter-mediated cytotoxic properties","volume":"49","author":"Liu","year":"2013","journal-title":"Chem. Commun."},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Wo\u017aniak, M., Pastuch-Gawo\u0142ek, G., Makuch, S., Wi\u015bniewski, J., Kren\u00e1cs, T., Hamar, P., Gamian, A., Szeja, W., Szkudlarek, D., and Krawczyk, M. (2021). In Vitro and In Vivo Efficacy of a Novel Glucose-Methotrexate Conjugate in Targeted Cancer Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041748"},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Domi\u0144ski, A., Domi\u0144ska, M., Skonieczna, M., Pastuch-Gawo\u0142ek, G., and Kurcok, P. (2022). Shell-Sheddable Micelles Based on Poly(ethylene glycol)-hydrazone-poly[R,S]-3-hydroxybutyrate Copolymer Loaded with 8-Hydroxyquinoline Glycoconjugates as a Dual Tumor-Targeting Drug Delivery System. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020290"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jare.2022.09.007","article-title":"Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells","volume":"49","author":"Zhu","year":"2023","journal-title":"J. Adv. Res."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/0008-5472.CAN-15-1862","article-title":"Disrupting Hypoxia-Induced Bicarbonate Transport Acidifies Tumor Cells and Suppresses Tumor Growth","volume":"76","author":"McIntyre","year":"2016","journal-title":"Cancer Res."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neo.2022.01.003","article-title":"Targeting hypoxia regulated sodium driven bicarbonate transporters reduces triple negative breast cancer metastasis","volume":"25","author":"Carroll","year":"2022","journal-title":"Neoplasia"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"26066","DOI":"10.18632\/oncotarget.15257","article-title":"Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer","volume":"8","author":"Chang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"De Vita, A., Liverani, C., Molinaro, R., Martinez, J.O., Hartman, K.A., Spadazzi, C., Miserocchi, G., Taraballi, F., Evangelopoulos, M., and Pieri, F. (2021). Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-84492-3"},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Nief, C.A., Gonzales, A., Chelales, E., Agudogo, J.S., Crouch, B.T., Nair, S.K., and Ramanujam, N. (2022). Targeting Tumor Acidosis and Regulatory T Cells Unmasks Anti-Metastatic Potential of Local Tumor Ablation in Triple-Negative Breast Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158479"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"104262","DOI":"10.1016\/j.cellimm.2020.104262","article-title":"The Exosomes Derived from CAR-T Cell Efficiently Target Mesothelin and Reduce Triple-Negative Breast Cancer Growth","volume":"360","author":"Yang","year":"2021","journal-title":"Cell. Immunol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1483\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:27:23Z","timestamp":1760106443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":235,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cancers16081483"],"URL":"https:\/\/doi.org\/10.3390\/cancers16081483","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]}}}